Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02374242 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Study acronym: ABC
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints: details revised at 3 of 11 entries Site details revised at 1 of 4 sitesv18 Show 1 more changeShow less
    • Site details revised at 1 of 4 sites
  2. 2 versions Re-verified since Mar 17, 2024, no change to tracked fieldsv16-v17
  3. Completion date: Dec 2022 to Dec 2028v15
  4. 4 versions Re-verified since Apr 10, 2019, no change to tracked fieldsv11-v14
  5. Primary completion date changed from estimate of Nov 2018 to Sep 4, 2017v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary completion date: Apr 2018 to Nov 2018 Start date: Oct 2014 to Nov 4, 2014v9 Show 1 more changeShow less
    • Start date: Oct 2014 to Nov 4, 2014
  2. Primary completion date: Dec 2017 to Apr 2018 Completion date: Dec 2020 to Dec 2022v8 Show 1 more changeShow less
    • Completion date: Dec 2020 to Dec 2022
  3. Trial status: Recruiting to Active, Not Recruiting Site details revised at 4 of 4 sitesv7 Show 1 more changeShow less
    • Site details revised at 4 of 4 sites
  4. 2 versions Re-verified since Nov 8, 2016, no change to tracked fieldsv5-v6
  5. Enrollment target: 75 to 76 Study sites: 3 to 4 · Eligibility criteria expanded, about 49 wordsv4 Show 2 more changesShow less
    • Study sites: 3 to 4
    • Eligibility criteria expanded, about 49 words

    See this version in full on ClinicalTrials.gov ↗

  6. Primary completion date: Oct 2017 to Dec 2017 Completion date: Oct 2020 to Dec 2020v3 Show 1 more changeShow less
    • Completion date: Oct 2020 to Dec 2020
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research project is to test the effectiveness of nivolumab versus nivolumab together with ipilimumab for the treatment of melanoma brain metastases. Patients are eligible to join this study if they are aged 18 years or above and have been diagnosed with melanoma with brain metastases.
Trial Details
NCT Number NCT02374242
Lead Sponsor Melanoma Institute Australia
Collaborators: Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb
Conditions Melanoma, Brain Metastases
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov